Abstract
In chronic inflammatory diseases such as rheumatoid arthritis (RA), systemic inflammation appears as an independent risk factor, contributing to increased cardiovascular mortality. This high cardiovascular mortality reveals the existence of accelerated atherosclerosis, the pathogenesis of which may be associated with traditional risk factors such as smoking, hypertension, dyslipidemia, deterioration of insulin sensitivity, and less traditional risk factors such as hyperhomocysteinemia, inflammatory conditions and endothelial dysfunction. Control of systemic inflammation theoretically provides a means of preventing this higher cardiovascular mortality among RA patients. In this review we address the question of the impact of anti-rheumatic drugs currently used in RA, such as non-steroidal anti-inflammatory drugs (e.g. non-selective or cyclooxygenase-2 selective inhibitors), steroidal anti-inflammatory drugs (glucocorticoids), traditional disease-modifying anti-rheumatic drugs (e.g. methotrexate) or biologics (e.g. anti-tumour necrosis factor alpha anti-tumour necrosis factor alpha) on cardiovascular diseases in RA patients. We also discuss the specific mechanisms involved in the differential cardiovascular effects of these therapeutic agents.
Keywords: Rheumatoid arthritis, cardiovascular diseases, disease-modifying anti-rheumatic drugs, glucocorticoids, nonsteroidal anti-inflammatory drugs, biologics
Current Vascular Pharmacology
Title: Impact of Traditional Therapies and Biologics on Cardiovascular Diseases in Rheumatoid Arthritis
Volume: 6 Issue: 3
Author(s): Jean-Frederic Boyer, Alain Cantagrel and Arnaud Constantin
Affiliation:
Keywords: Rheumatoid arthritis, cardiovascular diseases, disease-modifying anti-rheumatic drugs, glucocorticoids, nonsteroidal anti-inflammatory drugs, biologics
Abstract: In chronic inflammatory diseases such as rheumatoid arthritis (RA), systemic inflammation appears as an independent risk factor, contributing to increased cardiovascular mortality. This high cardiovascular mortality reveals the existence of accelerated atherosclerosis, the pathogenesis of which may be associated with traditional risk factors such as smoking, hypertension, dyslipidemia, deterioration of insulin sensitivity, and less traditional risk factors such as hyperhomocysteinemia, inflammatory conditions and endothelial dysfunction. Control of systemic inflammation theoretically provides a means of preventing this higher cardiovascular mortality among RA patients. In this review we address the question of the impact of anti-rheumatic drugs currently used in RA, such as non-steroidal anti-inflammatory drugs (e.g. non-selective or cyclooxygenase-2 selective inhibitors), steroidal anti-inflammatory drugs (glucocorticoids), traditional disease-modifying anti-rheumatic drugs (e.g. methotrexate) or biologics (e.g. anti-tumour necrosis factor alpha anti-tumour necrosis factor alpha) on cardiovascular diseases in RA patients. We also discuss the specific mechanisms involved in the differential cardiovascular effects of these therapeutic agents.
Export Options
About this article
Cite this article as:
Boyer Jean-Frederic, Cantagrel Alain and Constantin Arnaud, Impact of Traditional Therapies and Biologics on Cardiovascular Diseases in Rheumatoid Arthritis, Current Vascular Pharmacology 2008; 6 (3) . https://dx.doi.org/10.2174/157016108784911975
DOI https://dx.doi.org/10.2174/157016108784911975 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Meet Our Editorial Board Member
Current Vascular Pharmacology High Fat Meal Increase of IL-17 is Prevented by Ingestion of Fruit Juice Drink in Healthy Overweight Subjects
Current Pharmaceutical Design Decreased Expression and Altered Methylation of Syncytin-1 Gene in Human Placentas Associated with Preeclampsia
Current Pharmaceutical Design The Roles of MicroRNAs in Heart Diseases: A Novel Important Regulator
Current Medicinal Chemistry Limonin, A Citrus Limonoid, had no Apparent Effect on Cognitive Dysfunction in Mice with Chronic Cerebral Hypoperfusion
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Ocular Biomarkers of Alzheimer’s Disease
Central Nervous System Agents in Medicinal Chemistry Novel Approaches to the Pharmacotherapy of Obesity
Current Pharmaceutical Design Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity
Current Cancer Therapy Reviews Hypertension, Cognitive Impairment and Dementia: An Epidemiological Perspective
Current Hypertension Reviews Patient Engagement in Randomized Controlled Tai Chi Clinical Trials among the Chronically Ill
Reviews on Recent Clinical Trials Mediterranean Diet and the Metabolic Syndrome: The Role of Protein
Current Nutrition & Food Science 25OH-Vitamin D3 Levels in Obesity and Metabolic Syndrome—Unaltered in Young and not Correlated to Carotid IMT in All Ages
Current Pharmaceutical Design Chemical and Medicinal Versatility of Substituted 1,4-Dihydropyridines
Current Bioactive Compounds Mitochondrial Dysfunction and Lipid Homeostasis
Current Drug Metabolism Cerebrovascular Complications After Heart Transplantation
Current Cardiology Reviews Renal Blood Flow Dynamics in Inbred Rat Strains Provides Insight into Autoregulation
Current Vascular Pharmacology The Role of Mitochondrial Dysfunction in Heart Failure and Potential Therapeutic Targets
Current Pharmaceutical Design High Prevalence of AH in HIV Patients on ART, in Bahia, Brazil
Current HIV Research Cardiovascular Effects of Micromeria graeca (L.) Benth. ex Rchb in Normotensive and Hypertensive Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Vigna unguiculata Trypsin Inhibitor: A Protein with Versatile Biological Applications
Current Enzyme Inhibition